Skip to main content
Clinical Trials/NCT06626386
NCT06626386
Recruiting
Not Applicable

Determination of Prostate-specific Antigen in Capillary Blood (PSA-Cap)

Heinrich-Heine University, Duesseldorf1 site in 1 country200 target enrollmentJune 1, 2024
ConditionsProstate Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Heinrich-Heine University, Duesseldorf
Enrollment
200
Locations
1
Primary Endpoint
Accuracy of PSA measurement in capillary blood vs. venous blood
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The aim of the PSA-Cap study is to test the comparability of measurements of total PSA in serum from venipuncture and in serum from capillary blood using anonymized diagnostic blood samples from patients. Furthermore, a stability test of the samples is carried out after storage at room temperature for 24, 72/96 and 168 hours. Particular attention is paid to the comparability of the measurement results and the influence of the transportation time.

Detailed Description

Interventions that are conducted with the PSA-Cap trial are the collection of capillary blood (6 droplets) from the fingertip during regular PSA testing in venous blood. PSA is measured in the serum fraction of both samples (capillary and venous) using the established routine procedure, either immediately or after simulation of common transport conditions (intermediate storage for 24; 72/96 h and 168 h at 22 °C). Control measurements include parameters of cell lysis (LDH, HIL check) and general protein stability (albumin). The patient samples used are anonymized at the source by means of a consecutive series of numbers. The anonymized result groups are compared.

Registry
clinicaltrials.gov
Start Date
June 1, 2024
End Date
October 31, 2024
Last Updated
last year
Study Type
Observational
Sex
Male

Investigators

Sponsor
Heinrich-Heine University, Duesseldorf
Responsible Party
Principal Investigator
Principal Investigator

Dr. med. Rouvier Al-Monajjed

Oberarzt

Heinrich-Heine University, Duesseldorf

Eligibility Criteria

Inclusion Criteria

  • Men aged from 45 to 70 years
  • Informed consent for PSA measurement for prostate cancer screening

Exclusion Criteria

  • Patients unable to give consent

Outcomes

Primary Outcomes

Accuracy of PSA measurement in capillary blood vs. venous blood

Time Frame: After 0 h, 1 d, 3/4 d and 7 d

Secondary Outcomes

  • PSA stability in serum fraction of both samples (capillary and venous)(After 0 h, 1 d, 3/4 d and 7 d)

Study Sites (1)

Loading locations...

Similar Trials